Find clinical trials for Adenocarcinoma in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Adenocarcinoma trials near Paris, Île-de-France, FRA:
with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...
Phase 3
Paris, France and 156 other locations
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic...
Phase 2
Paris, France and 26 other locations
for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for ...
Phase 3
Paris, France and 197 other locations
mFOLFIRINOX in the treatment of locally advanced pancreatic ductal adenocarcinoma.The study drug which is tested is the NP137 in association...
Phase 1
Paris, France and 8 other locations
Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma...
Phase 1, Phase 2
Paris, France and 15 other locations
The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-...
Phase 2
Paris 10, France and 30 other locations
and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).This study aims to explore whether blockade of Transforming Gr...
Phase 3
Paris, France and 113 other locations
TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination wit...
Phase 2
Paris, France and 27 other locations
Gastric adenocarcinoma is the 4th most frequent cancer and the 2nd leading cause of cancer mortality. Most of the patients have metastatic, ...
Phase 2
Paris, France and 34 other locations
The purpose of this study is to determine the Objective Response Rate (ORR) of zolbetuzimab as a single agent as assessed by an independent central r...
Phase 2
Paris, France and 25 other locations
Clinical trials
Research sites
Resources
Legal